Asia-Pacific Syndromic Multiplex Diagnostic Market, By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others) Industry Trends and Forecast to 2029
Market Definition and Insights
Syndromic multiplex diagnostic is a type of advanced diagnostic test that is utilized to detect various types of infection diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among other types of infectious diseases. Syndromic multiplex diagnostic also helps the clinicians or hospitals to detect the symptoms and signs of the various types of diseases. This lets the health care providers provide the right treatment for the patients and offer more precise outcomes and care that can be performed more quickly.
Syndromic multiplex testing is used to diagnose many pathogens simultaneously. In the syndromic multiplex diagnostic, various types of reagents & consumables and instruments & accessories are used, which helps maintain accuracy and provide fast diagnosis results. These multiplex tests are rapidly diagnosed with certain infections, allowing clinical management decisions to be made promptly. The tests based on multiplex technology are known as test panel. The panels used in syndromic testing are designed to diagnose multiple diseases associated with the same or similar type of syndrome. These panels help evaluate the cause of the disease at the point of care. Gastrointestinal panels and respiratory panels are the types of syndromic panels.
Syndromic multiplex testing utilizes the advanced technology of multiplex PCR which provides accurate and fast diagnostic results, with the help of the multiple panels which is used in syndromic multiplex diagnostic to provide diagnostic results within an hour. The new generations of syndromic multiplex can rapidly identify the common type of pathogens in the respiratory specimens, blood and cerebrospinal. The use of multiplex panels is associated with quicker turnaround time, reduction of other unnecessary laboratory tests, faster diagnosis and targeted treatment.
Data Bridge Market Research analyses that the Asia-Pacific syndromic multiplex diagnostic market will grow at a CAGR of 9.6% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others) |
|
Countries Covered |
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific |
|
Market Players Covered |
BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Prominex Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany), MiRXES Pte Ltd (Singapore) |
Syndromic Multiplex Diagnostic Market Dynamics
Drivers
- Increasing demand for fast and accurate results
Fast and accurate syndromic diagnostic helps healthcare professionals to provide efficient medication at the proper time. Accurate syndromic diagnostic testing is used for various pathogens in a single test reaction. This test helps provide more comprehensive, accurate, and realistic results in critical care. Hence, the high demand for fast and accurate results drives the market growth.
- Rise in prevalence of infectious diseases
The rising incidence of infectious bacterial and viral diseases impacts the market's demand because, in the syndromic testing, multiplex real-time PCR technique and the syndromic approach are used for molecular diagnostics of infectious diseases.
Opportunity
- Rising Diagnostic Healthcare Expenditure
The growing healthcare expenditure is expected to increase the availability of services and affordability for the population to opt for better and more precise diagnostic services to manage their diseases. The increase in healthcare expenditure ensures better availability of diagnostic services. Hence, huge health care expenditure is a favourable factor and is acting as an opportunity for the growth of the syndromic multiplex diagnostic market.
Restraints/Challenges
- High Cost of Diagnostic Products
The multiplex syndromic testing applications utilize the real-time Polymerase chain reaction (PCR), which delivers the results with amplification curves and correct values. The instruments used in the syndromic multiplex diagnostic require high maintenance costs. Hence, the high cost of instruments is a challenge for the market.
Post COVID-19 Impact on Syndromic Multiplex Diagnostic market
COVID-19 has positively affected the market. Market players are launching different products for the detection of the SARS-CoV virus. There is an increase in approval of products by regulatory bodies after post COVID-19, which leads to a rise in market growth.
Recent Development
- In January 2022, QIAGEN announced the enhancements in the commercialization of the QIAstat-Dx syndromic testing menu. This enhancement will help the company increase its revenue in the coming years.
Syndromic Multiplex Diagnostic Market Scope
The syndromic multiplex diagnostic market is categorized into five segments: product and services, infection type, disease, panels type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Services
- Reagents & Consumables
- Instruments, Software & Accessories
- Services
Based on products and services, the Asia-Pacific syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services.
Infection Type
- Viral
- Bacterial
- Parasites
- Fungal
Based on infection type, the Asia-Pacific syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal
Disease
- Respiratory Infection
- Gastroneteritis
- Sexually Transmitted Infections
- Sepsis
- Meningitis
- Others
Based on disease, the Asia-Pacific syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others
Panels Type
- Respiratory Panel
- GI-Enteric Panel
- Sexually Transmitted Disease Panel
- Blood-Sepsis Panel
- Meningitis Panel
- Others
Based on panels type, the Asia-Pacific syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others
End User
- Hospitals
- Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
- Research Institutes
- Others
Based on end user, the Asia-Pacific syndromic multiplex diagnostic market is segmented into clinical laboratories, hospitals, pharmaceutical & biotechnology companies, research institutes and others
Syndromic Multiplex Diagnostic Market Regional Analysis/Insights
The syndromic multiplex diagnostic market is analyzed, and market size insights and trends are provided by country, product and services, infection type, disease, panels type and end user, as referenced above.
The countries covered in the report are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific.
China syndromic multiplex diagnostic market is expected to grow due to an increase in the prevalence of infectious diseases and a rise in demand for early and accurate diagnosis. Also, rising initiatives by global players to launch new products will further boost the market growth in the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels is considered while providing forecast analysis of the country data.
Syndromic Multiplex Diagnostic Market Share Analysis
The syndromic multiplex diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Saudi Arabia presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the syndromic multiplex diagnostic market.
Some of the major players operating in the Asia-Pacific syndromic multiplex diagnostic market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc., Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid (A Subsidiary of Danaher), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Biocartis, QuantuMDx Group Ltd., Prominex Inc, Curetis (A Subsidiary of OpGen, Inc.), MiRXES Pte Ltd. among others.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT AND SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021)
5 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES
6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES
6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING
6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS
6.2 RESTRAINTS
6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS
6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE
6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS
6.4 CHALLENGES
6.4.1 PRODUCT RECALLS
6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
7 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES
7.1 OVERVIEW
7.2 REAGENTS & CONSUMABLES
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES
7.4 SERVICES
8 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE
8.1 OVERVIEW
8.2 VIRAL
8.2.1 CORONAVIRUS
8.2.2 INFLUENZA VIRUS
8.2.3 ADENOVIRUS
8.2.4 RHINOVIRUS
8.2.5 ROTAVIRUS
8.2.6 OTHERS
8.3 BACTERIAL
8.3.1 PNEUMONIAE
8.3.2 BORDETELLA PERTUSSIS
8.3.3 STAPHYLOCOCCUS
8.3.4 OTHERS
8.4 PARASITES
8.5 FUNGAL
9 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS
9.3 GASTROENTERITIS
9.4 SEXUALLY TRANSMITTED INFECTIONS
9.5 SEPSIS
9.6 MENINGITIS
9.7 OTHERS
10 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE
10.1 OVERVIEW
10.2 RESPIRATORY PANEL
10.3 GI-ENTERIC PANEL
10.4 SEXUALLY TRANSMITTED DISEASE PANEL
10.5 BLOOD-SEPSIS PANEL
10.6 MENINGITIS PANEL
10.7 OTHERS
11 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICAL LABORATORIES
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.5 RESEARCH INSTITUTES
11.6 OTHERS
12 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 INDIA
12.1.4 SOUTH KOREA
12.1.5 AUSTRALIA
12.1.6 SINGAPORE
12.1.7 THAILAND
12.1.8 MALAYSIA
12.1.9 INDONESIA
12.1.10 PHILIPPINES
12.1.11 REST OF ASIA-PACIFIC
13 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMÉRIEUX SA)
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY
15.3.1 COMPANY SNAPSHOT
15.3.2 RECENT FINANCIALS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 CEPHEID (A SUBSIDIARY OF DANAHER)
15.4.1 COMPANY SNAPSHOT
15.4.2 RECENT FINANCIALS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 QIAGEN
15.5.1 COMPANY SNAPSHOT
15.5.2 RECENT FINANCIALS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AKONNI BIOSYSTEMS, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 APPLIED BIOCODE, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 BD
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIOCARTIS
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 BIO-RAD LABORATORIES, INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.)
15.13.1 COMPANY SNAPSHOT
15.13.2 RECENT FINANCIALS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 HOLOGIC, INC.
15.14.1 COMPANY SNAPSHOT
15.14.2 RECENT FINANCIALS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 MIRXES PTE LTD.
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 NANŌMIX, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 PROMINEX INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 QUANTUMDX GROUP LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.19 SEEGENE INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENTS
15.2 SIEMENS HEALTHCARE GMBH
15.20.1 COMPANY SNAPSHOT
15.20.2 RECENT FINANCIALS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENT
15.21 THERMOFISHER SCIENTIFIC INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 RECENT FINANCIALS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tabela
TABLE 1 COST OF THE PRODUCT
TABLE 2 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 37 ASIA-PACIFIC BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 42 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 43 CHINA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 44 CHINA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 45 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 46 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 47 CHINA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 49 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 50 JAPAN VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 51 JAPAN BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 52 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 53 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 54 JAPAN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 56 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 57 INDIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 58 INDIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 59 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 60 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 61 INDIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 62 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 63 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 64 SOUTH KOREA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 65 SOUTH KOREA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 66 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 67 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 68 SOUTH KOREA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 69 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 70 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 71 AUSTRALIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 72 AUSTRALIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 73 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 74 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 75 AUSTRALIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 76 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 77 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 78 SINGAPORE VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 79 SINGAPORE BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 80 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 81 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 82 SINGAPORE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 84 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 85 THAILAND VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 86 THAILAND BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 87 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 88 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 89 THAILAND SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 91 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 92 MALAYSIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 93 MALAYSIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 94 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 95 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 96 MALAYSIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 97 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 98 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 99 INDONESIA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 100 INDONESIA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 101 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 102 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 103 INDONESIA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 105 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 106 PHILIPPINES VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 107 PHILIPPINES BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 108 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 109 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 110 PHILIPPINES SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 111 REST OF ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD
FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA
FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE
FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019
FIGURE 18 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021
FIGURE 19 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION)
FIGURE 20 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029)
FIGURE 21 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021
FIGURE 23 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION)
FIGURE 24 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029)
FIGURE 25 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021
FIGURE 27 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION)
FIGURE 28 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029)
FIGURE 29 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021
FIGURE 31 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION)
FIGURE 32 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029)
FIGURE 33 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021
FIGURE 35 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 36 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021)
FIGURE 39 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021)
FIGURE 40 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 ASIA-PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029)
FIGURE 43 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
